Zhongheng Group: Subsidiaries and Grandchildren Companies' Some Products Proposed to Be Selected for National Centralized Procurement of Drugs for Continued Purchase

2026-03-10 22:50:33

Zhongheng Group announced that some products from its controlling subsidiary Chongqing Laimei Pharmaceutical and its wholly owned subsidiary Hunan Kangyuan Pharmaceutical are scheduled to continue procurement under the national centralized procurement agreement after the expiration of the selected drug list. In 2024, the sales revenue of these products is expected to be 106 million yuan, accounting for 4.68% of the company’s annual operating income; in the first three quarters of 2025, sales revenue was 66.0742 million yuan, accounting for 3.39% of the same period’s operating income.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.